Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!
Recent positives news flow reaffirms our confidence in further growth of launched product JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET, partnered with Novartis for Ex-US rights) and Incyte’s (INCY) maturing pipeline. PhII data of oral RA drug Barcitinib (PhIII) partnered with Lilly looks cleaner than PFE’s launched oral RA drug (Xeljanz, tofacitinib, JAK1/3 inhibitor) with efficacy sustainable at 52 weeks. JAKAFI’s expanded dosing guidance for patients with low platelet counts along with flexibility for subsequent dose modifications should boost uptake. First evidence of a drug therapy that may stabilize or improve bone marrow fibrosis is encouraging because the only other proven option for MF is bone marrow transplantation. Data presented at EHA ’13, from three-year follow-up analysis of the COMFORT-II study indicated that 52% reduction in … For more detail, please read our report released on June 18, 2013, titled, “Incyte - Label Expansion + Upcoming Milestones Sufficient Reason to Remain Invested for Long Term!”
